AbbVie Inc. Announces Exclusive Licensing Agreement and Phase 1 Clinical Trial for Pioneering ISB 2001 Trispecific Antibody in Multiple Myeloma Treatment
AbbVie Inc. and Ichnos Glenmark Innovation have announced an exclusive global licensing agreement for ISB 2001, a first-in-class trispecific antibody targeting CD38, BCMA, and CD3. ISB 2001 is designed for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) and is currently in Phase 1 clinical trials. Under the agreement, AbbVie will gain exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China. IGI will receive an upfront payment of $700 million and is eligible for additional milestone payments and royalties. This partnership aims to accelerate the development and potential market introduction of ISB 2001, though no specific dates for future presentations of study results were announced.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG27470) on July 10, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。